Welcome and Introduction to Vi3C

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Deborah Collyar: What's In It for Patients?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Focus on Optimized Dosing of Ibrutinib Panel Discussion

May

Today In Oncology

Welcome and Introduction to Vi3C

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Deborah Collyar: What's In It for Patients?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Curing Most Leukemias on the Horizon: A 5-Decade MD Anderson Perspective on Leukemia Research

Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants

Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC

Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS

High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC